Literature DB >> 11934878

Epithelial cell-derived human beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway.

François Niyonsaba1, Kazuhisa Iwabuchi, Hiroshi Matsuda, Hideoki Ogawa, Isao Nagaoka.   

Abstract

Mast cells are known to accumulate at the sites of inflammation in response to chemoattractants generated in the local milieu. Since human beta-defensin-2 (hBD-2) is generated in several epithelial tissues where mast cells are present and because we have recently reported that this human antibacterial peptide induces mast cell degranulation, we thus hypothesized that hBD-2 could be a mast cell chemotaxin. Here we report that hBD-2 directly and specifically induces mast cell migration with an optimal concentration of 3 microg/ml. Checkerboard analysis showed that the migration was more chemotactic rather than chemokinetic. Moreover, Scatchard analysis using 125I-labeled hBD-2 revealed that mast cells have at least two classes of receptors, high- and low-affinity receptors, for this peptide. Moreover, the competitive binding assay suggested that hBD-2 is unlikely to utilize CCR6, a functional receptor for hBD-2-mediated dendritic and T cell migration, on mast cells. In addition, treatment of mast cells with G protein inhibitor, pertussis toxin, and phospholipase C inhibitor, U-73122, abolished the cell chemotaxis in response to hBD-2, indicating that the G protein-phospholipase C signaling pathway is involved in hBD-2-induced mast cell activation. Thus, we suggest that hBD-2, which was originally believed to be involved in innate host defense, may participate in the recruitment of mast cells to inflammation foci.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11934878     DOI: 10.1093/intimm/14.4.421

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  56 in total

Review 1.  Chemokines meet defensins: the merging concepts of chemoattractants and antimicrobial peptides in host defense.

Authors:  Manuela Dürr; Andreas Peschel
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

Review 2.  Antimicrobial peptides in periodontal innate defense.

Authors:  Sven-Ulrik Gorr
Journal:  Front Oral Biol       Date:  2011-11-11

Review 3.  Antimicrobial aspects of inflammatory resolution in the mucosa: a role for proresolving mediators.

Authors:  Eric L Campbell; Charles N Serhan; Sean P Colgan
Journal:  J Immunol       Date:  2011-10-01       Impact factor: 5.422

Review 4.  Roles of antimicrobial peptides such as defensins in innate and adaptive immunity.

Authors:  J J Oppenheim; A Biragyn; L W Kwak; D Yang
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

5.  Defensins and other antimicrobial peptides at the ocular surface.

Authors:  Alison M McDermott
Journal:  Ocul Surf       Date:  2004-10       Impact factor: 5.033

Review 6.  The emerging role of peptides and lipids as antimicrobial epidermal barriers and modulators of local inflammation.

Authors:  N K Brogden; L Mehalick; C L Fischer; P W Wertz; K A Brogden
Journal:  Skin Pharmacol Physiol       Date:  2012-04-26       Impact factor: 3.479

Review 7.  AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense.

Authors:  Yuping Lai; Richard L Gallo
Journal:  Trends Immunol       Date:  2009-02-13       Impact factor: 16.687

Review 8.  Host defense peptides in wound healing.

Authors:  Lars Steinstraesser; Till Koehler; Frank Jacobsen; Adrien Daigeler; Ole Goertz; Stefan Langer; Marco Kesting; Hans Steinau; Elof Eriksson; Tobias Hirsch
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

Review 9.  The roles of antimicrobial peptides in innate host defense.

Authors:  Gill Diamond; Nicholas Beckloff; Aaron Weinberg; Kevin O Kisich
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

10.  Expression of human beta-defensins in conjunctival epithelium: relevance to dry eye disease.

Authors:  Srihari Narayanan; William L Miller; Alison M McDermott
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-09       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.